175358-02-8

Basic information

• Product Name: 4,6-Dichloropyrido[3,2-d]pyrimidine
• Synonyms: 4,6-Dichloropyrido[3,2-d]pyrimidine
• CAS NO: 175358-02-8
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.028
• Mol File: 175358-02-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 314.616 °C at 760 mmHg
• Flash Point: 173.301 °C
• Appearance: /
• Density: 1.573
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.89±0.30(Predicted)
• CAS DataBase Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)
• EPA Substance Registry System: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)

Safety Data

• Hazardous Substances Data: 175358-02-8(Hazardous Substances Data)

Usage

General Description

4,6-Dichloropyrido[3,2-d]pyrimidine is a chemical compound with the molecular formula C7H3Cl2N3. It belongs to the class of organic compounds known as pyrido[3,2-d]pyrimidines, which are polycyclic aromatic compounds containing a pyrido[3,2-d]pyrimidine moiety, which consists of a pyridine ring fused to a pyrimidine ring. It's less commonly utilized and not as widely studied, thus its potential applications are still largely unknown. Acquiring an understanding of its reactivity and chemical interactions could vastly contribute to its potential uses in various chemical-based industries.

InChI:InChI=1/C7H3Cl2N3/c8-5-2-1-4-6(12-5)7(9)11-3-10-4/h1-3H

Upstream product

• 171178-33-9 6-chloropyrido<3,2-d>pyrimidin-4(3H)-one 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 171178-33-9 6-chloropyrido[3,2-d]pyrimidin-4(1H)-one 
• 1242446-83-8 4-chloropyrido[3,2-d]pyrimidin-6-ol 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 2402-78-0 2,6-dichloropyridine 
• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 

Downstream Products

• 855995-77-6 4-[2-(6-chloro-pyrido [3,2-d]pyrimidin-4-ylamino)-phenoxy]-butyric acid ethyl ester 
• 855995-88-9 {2-[(allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenyl}-(6-chloro-pyrido [3,2-d] pyrimidin-4-yl)-amine 
• 1240349-48-7 C₁₆H₁₃ClN₄O₂ 
• 1240349-57-8 C₂₅H₂₁ClN₆O 
• 1240349-49-8 C₁₆H₁₂ClN₃O₂S 
• 1242446-26-9 6-chloro-4-(3-(trifluoromethyl)phenyl)pyrido[3,2-d]pyrimidine 
• 1293982-40-7 6-chloro-4-(p-tolylamino)pyrido[3,2-d]pyrimidine 
• 1400668-23-6 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1400668-15-6 6-chloro-4-(cyclohexylthio)pyrido[3,2-d]pyrimidine 
• 1400667-72-2 N-(5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1400667-73-3 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-74-4 N-(5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-75-5 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1400667-76-6 N-(2-chloro-5-(4-(1-methylpiperidin-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 

Relevant articles and documents

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

Design, synthesis and bioactivity evaluation of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as mnk and HDAC inhibitors

Both HDACs and Mnks play important role in translating multiple oncogenic signaling pathways during oncogenesis. As HDAC and Mnk are highly expressed in a variety of tumors; thus simultaneous inhibit HDAC and Mnk can increase the inhibition of tumor cell proliferation and provide a new way of inhibiting tumor growth. Based on the previous work and the merge pharmacophore method; we designed and synthesized a series of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as HDAC and Mnk dual inhibitors. Among them; compound A12 displayed good HDAC and Mnk inhibitory activity. In vitro antiproliferative assay; compound A12 exhibited the best antiproliferative activity against human prostate cancer PC-3 cells. Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk. These result indicated that A12 was a potent Mnk /HDAC inhibitor and will be further researched.